ERBB2 and cancer: Therefore, ongoing research increasingly emphasizes multiplexed assays, proteomic signatures, and integrative biomarker panels that move beyond reliance on individual markers like PSA, HER2, or CA125 to capture the complex biology of cancer more comprehensively.